|
Esophagitis
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
HR-Manometry showed a similar reduction in the LES pressure and 4sIRP; 24-h pH-monitoring showed however an abnormal exposure to acid in 38.4% of POEM patients, as compared to 17.1% of LHD patients (p < 0.01) and esophagitis was found in 37.4% of the POEM and 15.2% of LHD patients (p < 0.05).
|
31848870 |
2020 |
|
Lung diseases
|
0.010 |
GeneticVariation
|
group |
BEFREE |
We identify 14 novel loci (P<5 × 10(-8)) in or near ENSA, RNU5F-1, KCNS3, AK097794, ASTN2, LHX3, CCDC91, TBX3, TRIP11, RIN3, TEKT5, LTBP4, MN1 and AP1S2, and two novel signals at known loci NPNT and GPR126, providing a basis for new understanding of the genetic determinants of these traits and pulmonary diseases in which they are altered.
|
26635082 |
2015 |
|
Neoplasm Metastasis
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Nephronectin is Correlated with Poor Prognosis in Breast Cancer and Promotes Metastasis via its Integrin-Binding Motifs.
|
29539586 |
2018 |
|
Neoplasm Metastasis
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
We recently reported intracellular NPNT as a potential prognostic marker in breast cancer and that NPNT promotes metastasis in an integrin-dependent manner.
|
30524949 |
2018 |
|
Neoplasm Metastasis
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Nephronectin (NPNT) is an extracellular matrix protein which has shown biological activities in breast cancer metastases and osteoblasts differentiation.
|
30591862 |
2018 |
|
Malignant neoplasm of breast
|
0.050 |
Biomarker
|
disease |
BEFREE |
Recently, deregulation of POEM was found in breast cancer.
|
18271919 |
2008 |
|
Malignant neoplasm of breast
|
0.050 |
Biomarker
|
disease |
BEFREE |
Thus, we proposed that cancer secreted NPNT may be a novel marker with potential value of prediction and diagnosis of breast cancer bone metastases.
|
30591862 |
2018 |
|
Malignant neoplasm of breast
|
0.050 |
Biomarker
|
disease |
BEFREE |
Here, we used reverse-phase protein array (RPPA) to analyze NPNT-triggered intracellular signaling in the 66cl4 mouse breast cancer cell line.
|
30524949 |
2018 |
|
Esophageal Achalasia
|
0.050 |
Biomarker
|
disease |
BEFREE |
Types I and II achalasia respond well to POEM, LHM, and PD, while most studies have shown that type III achalasia responds better to POEM than to LHM and PD.
|
30881999 |
2019 |
|
Esophageal Achalasia
|
0.050 |
Biomarker
|
disease |
BEFREE |
We, therefore, designed this propensity score (PS) case-control study with the aim of evaluating how POEM compares to the long-standing laparoscopic Heller myotomy + Dor fundoplication (LHD) and verifying if it may really replace the latter as the first-line treatment for achalasia.
|
31848870 |
2020 |
|
Esophageal Achalasia
|
0.050 |
Biomarker
|
disease |
BEFREE |
Our study demonstrated that POEM is effective and safe for treating achalasia during the long-term followed up over 2 years.
|
30606216 |
2019 |
|
Esophageal Achalasia
|
0.050 |
Biomarker
|
disease |
BEFREE |
<i>Methods.</i> Clinical data of achalasia of cardia (AC) patients who underwent POEM in our center during January 2014 to January 2015 was collected (34 cases).
|
28316620 |
2017 |
|
Esophageal Achalasia
|
0.050 |
Biomarker
|
disease |
BEFREE |
POEM has been adopted worldwide as a treatment for achalasia.
|
28660419 |
2018 |
|
Breast Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Thus, we proposed that cancer secreted NPNT may be a novel marker with potential value of prediction and diagnosis of breast cancer bone metastases.
|
30591862 |
2018 |
|
Breast Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Here, we used reverse-phase protein array (RPPA) to analyze NPNT-triggered intracellular signaling in the 66cl4 mouse breast cancer cell line.
|
30524949 |
2018 |
|
Breast Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Recently, deregulation of POEM was found in breast cancer.
|
18271919 |
2008 |
|
Achalasia
|
0.050 |
Biomarker
|
disease |
BEFREE |
Our study demonstrated that POEM is effective and safe for treating achalasia during the long-term followed up over 2 years.
|
30606216 |
2019 |
|
Achalasia
|
0.050 |
Biomarker
|
disease |
BEFREE |
POEM has been adopted worldwide as a treatment for achalasia.
|
28660419 |
2018 |
|
Achalasia
|
0.050 |
Biomarker
|
disease |
BEFREE |
We, therefore, designed this propensity score (PS) case-control study with the aim of evaluating how POEM compares to the long-standing laparoscopic Heller myotomy + Dor fundoplication (LHD) and verifying if it may really replace the latter as the first-line treatment for achalasia.
|
31848870 |
2020 |
|
Achalasia
|
0.050 |
Biomarker
|
disease |
BEFREE |
<i>Background.</i> Here we aimed to evaluate and compare the efficacy and safety between partial full-thickness myotomy and circular muscle myotomy during POEM procedure in achalasia patients.
|
28316620 |
2017 |
|
Achalasia
|
0.050 |
Biomarker
|
disease |
BEFREE |
Types I and II achalasia respond well to POEM, LHM, and PD, while most studies have shown that type III achalasia responds better to POEM than to LHM and PD.
|
30881999 |
2019 |
|
Eczema
|
0.040 |
Biomarker
|
disease |
BEFREE |
There was moderate concordance between patient-reported AD severity (mild, moderate, and severe) and previously developed severity strata for oSCORAD (κ = 0.39), SCORAD (κ = 0.47), EASI (κ = 0.37), NRS-itch (κ = 0.49), POEM (κ = 0.37), and DLQI (κ = 0.40).
|
28905999 |
2018 |
|
Eczema
|
0.040 |
Biomarker
|
disease |
BEFREE |
In children with AD-only, clinical signs (objective SCORAD), symptoms (POEM, VAS pruritus, VAS sleeping problems) and previous treatment of AD were assessed to investigate disease patterns related to ADHD symptoms.
|
28975640 |
2018 |
|
Eczema
|
0.040 |
Biomarker
|
disease |
BEFREE |
The secondary outcomes were eczema severity over 1 year (4-weekly POEM), number of eczema exacerbations, disease-specific quality of life (QoL) (Dermatitis Family Impact Questionnaire), generic QoL (Child Health Utility-9 Dimensions) and type and quantity of topical steroid/calcineurin inhibitors prescribed.
|
30362939 |
2018 |
|
Dermatitis, Atopic
|
0.030 |
Biomarker
|
disease |
BEFREE |
In children with AD-only, clinical signs (objective SCORAD), symptoms (POEM, VAS pruritus, VAS sleeping problems) and previous treatment of AD were assessed to investigate disease patterns related to ADHD symptoms.
|
28975640 |
2018 |